Cowen Downgrades Orphazyme A/S (ORPHA:DC) (ORPH) to Market Perform, After Receiving FDA CRL
- Wall Street closes mixed, S&P 500 ends off record high
- Private Sector Employment Increased by 330,000 Jobs in July, Missing Expectations
- General Motors (GM) Misses on Profit Estimates as Bolt EV Recall Weighs on Earnings, Challenging Chip Situation and 'Cautious' Profit Outlook Pulling Shares Lower Says Analyst
- Exclusive-U.S. developing plan to require foreign visitors to be vaccinated -official
- Softbank-Backed Zymergen (ZY) Crashes Over 70% as CEO Departs, Product Revenue Not Possible in 2021 and 'Immaterial' in 2022, At Least 6 Firms Downgrade
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Cowen analyst Ritu Baral downgraded Orphazyme A/S (ORPHA:DC) (NASDAQ: ORPH) from Outperform to Market Perform.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tarena, Orphazyme, DiDi, and CorMedix and Encourages Investors to Contact the Firm
- JPMorgan Downgrades BAE Systems Plc (BA:LN) (BAESY) to Neutral
- UPDATE: KeyBanc Downgrades Inogen, Inc (INGN) to Sector Weight
Create E-mail Alert Related CategoriesDowngrades, Intl Ratings
Related EntitiesCowen & Co, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!